Beijing Beilu Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Xu Wang

Chief executive officer

CN¥1.8m

Total compensation

CEO salary percentage	n/a
CEO tenure	6.8yrs
CEO ownership	n/a
Management average tenure	6yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Beijing Beilu Pharmaceutical Co., Ltd's (SZSE:300016) Price

Feb 27

CEO

Xu Wang (40 yo)

6.8yrs

Tenure

CN¥1,762,200

Compensation

Mr. Xu Wang serves as General manager of Beijing Beilu Pharmaceutical Co., Ltd since December 11, 2017 and serves as its Chairman since August 01, 2019. He serves as Director at Beijing Beilu Pharmaceutica...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xu Wang	Chairman & GM	6.8yrs	CN¥1.76m	no data
Ni Zeng	Deputy GM	5.1yrs	CN¥687.20k	0.083% CN¥ 2.3m
Sen Li	Executive VP & COO	2.1yrs	CN¥1.65m	no data
Li Zong	Deputy GM & Director	9.5yrs	CN¥901.70k	0.033% CN¥ 907.5k
Zehui Shao	Deputy GM	6yrs	CN¥804.50k	0.077% CN¥ 2.1m
Gen Chang Zheng	Chief Engineer & Employee Representative Member of Supervisory Board	no data	CN¥535.40k	no data

6.0yrs

Average Tenure

43.5yo

Average Age

Experienced Management: 300016's management team is seasoned and experienced (6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xu Wang	Chairman & GM	9.3yrs	CN¥1.76m	no data
Ni Zeng	Deputy GM	5.1yrs	CN¥687.20k	0.083% CN¥ 2.3m
Li Zong	Deputy GM & Director	5.1yrs	CN¥901.70k	0.033% CN¥ 907.5k
Zehui Shao	Deputy GM	5.5yrs	CN¥804.50k	0.077% CN¥ 2.1m
Gen Chang Zheng	Chief Engineer & Employee Representative Member of Supervisory Board	16.3yrs	CN¥535.40k	no data
Qing Xiang	Non-Independent Director	2.4yrs	no data	no data
Ying Yang	Chairman of Supervisory Board	9.5yrs	no data	no data
Ying Dian Wang	Independent Director	5.5yrs	CN¥60.00k	no data
Bin Zheng	Independent Director	2.4yrs	CN¥60.00k	no data
Gang Cao	Independent Director	2.4yrs	CN¥60.00k	no data
Wei Jiang	Supervisor	2.4yrs	no data	no data
Fulong Wang	Director	less than a year	CN¥583.40k	0.011% CN¥ 292.4k

5.1yrs

Average Tenure

45.5yo

Average Age

Experienced Board: 300016's board of directors are considered experienced (5.1 years average tenure).

Beijing Beilu Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

High number of new directors

Less than half of directors are independent

Beijing Beilu Pharmaceutical Co., Ltd Elects Board Members

Beijing Beilu Pharmaceutical Co., Ltd, Annual General Meeting, Apr 20, 2022

Beijing Beilu Pharmaceutical Co., Ltd., Annual General Meeting, Apr 08, 2021

Recent updates

High number of new directors

Second quarter 2024 earnings released: EPS: CN¥0.016 (vs CN¥0.006 loss in 2Q 2023)

Beijing Beilu Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.024 (vs CN¥0.026 in 1Q 2023)

Beijing Beilu Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 22, 2024

Beijing Beilu Pharmaceutical Co., Ltd (SZSE:300016) Signed a Letter of intent to acquire 80% stake in Chengde Tianyuan Pharmaceuticals Co.,Ltd from Goldenmax International Group Ltd. (SZSE:002636) for CNY 248 million.

Beijing Beilu Pharmaceutical Co., Ltd (SZSE:300016) Signed a Letter of intent to acquire 80% stake in Chengde Tianyuan Pharmaceuticals Co.,Ltd from Goldenmax International Group Ltd. (SZSE:002636) for CNY 248 million.

Subdued Growth No Barrier To Beijing Beilu Pharmaceutical Co., Ltd's (SZSE:300016) Price

High number of new directors

Beijing Beilu Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.032 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.001 profit in 2Q 2022)

Beijing Beilu Pharmaceutical Co., Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 25, 2023

First quarter 2023 earnings released: EPS: CN¥0.026 (vs CN¥0.08 in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.027 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.14 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Beijing Beilu Pharmaceutical Co.,Ltd Announces the Implementation of Cash Dividend for 2019, Payable on 29 April 2022

Beijing Beilu Pharmaceutical Co., Ltd Elects Board Members

Investor sentiment deteriorated over the past week

Beijing Beilu Pharmaceutical Co., Ltd, Annual General Meeting, Apr 20, 2022

Beijing Beilu Pharmaceutical Co., Ltd Announces Final Cash Dividend for Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.054 in 1Q 2020)

Beijing Beilu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020

Beijing Beilu Pharmaceutical Co., Ltd., Annual General Meeting, Apr 08, 2021

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.70 in FY 2019)

Beijing Beilu Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥8.49

New 90-day low: CN¥9.02

New 90-day low: CN¥10.93

Third quarter earnings released

New 90-day low: CN¥11.04

Earnings released

New 90-day high - CN¥12.80

Beijing Beilu Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 08, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age